Journal
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Volume 65, Issue 12, Pages 2502-2504Publisher
OXFORD UNIV PRESS
DOI: 10.1093/jac/dkq381
Keywords
maraviroc; drug resistance; tropism; V3 loop; R5-tropic
Funding
- Fundacion Investigacion y Educacion en SIDA (F-IES)
- European Union [LSHP-CT-2006-037570]
- Red de Investigacion en SIDA (RIS) [ISCIII-RETIC-RD06/006]
- Fondo de Investigacion Sanitaria (FIS) [CP08/00214, CP0610284, PI06/01826, FI09/00868]
Ask authors/readers for more resources
Evaluation of the prevalence of V3 mutational patterns associated with maraviroc resistance in R5-using variants. V3 sequences were obtained from 809 plasma specimens collected from maraviroc-naive HIV-1-infected individuals on regular follow-up at Hospital Carlos III. Sequences considered to harbour R5-tropic viruses were examined for the presence of primary maraviroc resistance mutational patterns, as found in both in vitro and in vivo studies. A total of 498 R5-V3 sequences were identified. They belonged to recent HIV-1 seroconverters (55.6%), chronically antiretroviral-naive subjects (20.1%) and antiretroviral-experienced patients (24.3%). Most individuals (93.8%) were infected with HIV-1 subtype B. The overall prevalence of maraviroc resistance mutational patterns was low (< 5%). Likewise, specific polymorphisms 4L, 11R or 19S, recently found to be associated with lower clinical response to maraviroc, were found in < 2% of tested samples. The rate of maraviroc resistance patterns did not differ significantly according to length of HIV-1 infection, antiretroviral exposure or HIV-1 subtype. The prevalence of maraviroc resistance mutations is low in maraviroc-naive HIV-1-infected individuals.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available